

Mario A Eisenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6600539/publications.pdf>

Version: 2024-02-01

65
papers

9,216
citations

159585

30
h-index

118850

62
g-index

67
all docs

67
docs citations

67
times ranked

9766
citing authors

#	ARTICLE	IF	CITATIONS
1	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	27.0	2,233
2	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
3	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	7.1	696
4	Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. <i>Nature Medicine</i> , 1995, 1, 944-949.	30.7	590
5	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	7.1	552
6	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. <i>Nature</i> , 2014, 515, 134-137.	27.8	284
7	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. <i>European Urology</i> , 2017, 71, 740-747.	1.9	256
8	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m ²) and the Currently Approved Dose (25 mg/m ²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3198-3206.	1.6	218
9	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	12.4	205
10	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	2.6	202
11	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. <i>Journal of Clinical Oncology</i> , 2000, 18, 1440-1450.	1.6	176
12	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	10.7	149
13	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	1.8	129
14	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6863-6874.	7.0	122
15	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	5.0	111
16	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458.	1.9	109
17	COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. <i>Journal of Urology</i> , 2000, 164, 3-9.	0.4	100
18	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015, 75, 1518-1525.	2.3	88

#	ARTICLE	IF	CITATIONS
19	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	2.6	83
20	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	1.6	75
21	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	1.6	73
22	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	1.6	65
23	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate, 2016, 76, 1218-1226.	2.3	63
24	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	1.9	61
25	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	5.4	52
26	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
27	Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. European Urology, 2014, 66, 330-336.	1.9	48
28	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	1.9	48
29	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.8	37
30	Nivolumab plus ipilimumab, with or without enzalutamide, in AR-expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
31	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	2.0	34
32	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 2021, 144, 302-309.	2.8	29
33	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	5.0	24
34	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	23
35	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
36	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	1.8	20

#	ARTICLE	IF	CITATIONS
37	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. <i>Urology</i> , 2004, 63, 114-119.	1.0	19
38	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. <i>Urology</i> , 2014, 83, 1444.e1-1444.e6.	1.0	19
39	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	2.3	19
40	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 387-395.	0.8	19
41	Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	1.0	16
42	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020, 20, 492.	2.6	16
43	AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2015, 33, 138-138.	1.6	14
44	The experience with suramin in advanced prostate cancer. <i>Cancer</i> , 1995, 75, 1927-1934.	4.1	10
45	Southwest oncology group strategies in prostatic carcinoma. <i>Journal of Surgical Oncology</i> , 1995, 11, 60-64.	1.4	9
46	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	2.8	7
47	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. <i>Cancers</i> , 2021, 13, 1284.	3.7	6
48	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸ F-DCFPyL. <i>Molecular Imaging</i> , 2022, 2022, 7056983.	1.4	6
49	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer—Playing the Right CARD. <i>New England Journal of Medicine</i> , 2019, 381, 2564-2566.	27.0	5
50	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. <i>Human Pathology</i> , 2020, 101, 70-79.	2.0	5
51	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629.	0.4	4
52	Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211000.	3.2	4
53	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	2.6	3
54	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Journal of Clinical Oncology</i> , 2015, 33, 336-336.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.4	2
56	The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 44-44.	1.6	2
57	A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 360-360.	1.6	2
58	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	2.3	2
59	Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su).. <i>Journal of Clinical Oncology</i> , 2012, 30, e15058-e15058.	1.6	1
60	Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model.. <i>Journal of Clinical Oncology</i> , 2012, 30, 37-37.	1.6	1
61	Metformin use and outcome of sunitinib treatment in diabetic patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 440-440.	1.6	1
62	Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC MO) after local therapy (tx).. <i>Journal of Clinical Oncology</i> , 2013, 31, 160-160.	1.6	0
63	Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2013, 31, 146-146.	1.6	0
64	Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?. <i>Journal of Clinical Oncology</i> , 2013, 31, 458-458.	1.6	0
65	Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 429-429.	1.6	0